Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | TP53 | P04637 | 3/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | TTR | P02766 | 3/20 | 0.77 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.65 |
| ▸ | TUBB | P07437 | 2/20 | 0.65 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.65 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.65 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.65 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.65 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.65 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.65 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.65 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.65 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2574064 | 1.00 | LMNA (0.77) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL1808387 | 0.93 | MEN1 (0.84) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL1808386 | 0.93 | MEN1 (0.84) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL18471992 | 0.90 | LMNA (0.69) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL3688258 | 0.89 | KDM4E (0.67) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL3688259 | 0.89 | KDM4E (0.67) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL10941162 | 0.89 | MAPT (0.81) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL2451780 | 0.89 | MAPT (0.81) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL11354408 | 0.89 | MAPT (0.81) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL16130494 | 0.88 | KDM4E (0.69) | LMNAMAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | BIOMOL INTERNATIONAL, INC. | 2006-01-19 | — | — | US | claimed |
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | disclosed |
| US-11419841-B2 | Uses of lipophenolic compounds | UNIVERSITE DE MONTPELLIER | 2022-08-23 | — | — | US | disclosed |
| EP-3134421-B1 | NEW LIPOPHENOL COMPOUNDS AND USES THEREOF | INST NAT SANTE RECH MED (FR) | 2022-04-20 | — | — | EP | disclosed |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2021-07-29 | — | — | US | disclosed |
| US-11014947-B2 | Lipophenol compounds and uses thereof | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2021-05-25 | — | — | US | disclosed |
| US-20200360334-A1 | New Uses of Lipophenolic Compounds | UNIVERSITE DE MONTPELLIER (FR) | 2020-11-19 | — | — | US | disclosed |
| US-10813934-B2 | Sirtuin modulators as inhibitors of cytomegalovirus | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-10-27 | — | — | US | disclosed |
| EP-3706732-A1 | NEW USES OF LIPOPHENOLIC COMPOUNDS | Université de Montpellier (FR) | 2020-09-16 | — | — | EP | disclosed |
| US-20100185006-A1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND PROCESSES FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY (US) | 2010-07-22 | — | — | US | disclosed |
| US-7714161-B2 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY (US) | 2010-05-11 | — | — | US | disclosed |
| WO-2009099643-A1 | USE OF SIRT1 ACTIVATORS OR INHIBITORS TO MODULATE AN IMMUNE RESPONSE | THE J. DAVID GLADSTONE INSTITUTES (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090012130-A1 | Strategies for Designing Drugs that Target the Sir2 Family of Enzymes | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY | 2008-10-16 | — | — | US | disclosed |
| EP-1753708-A4 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1753708-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | Brigham Young University (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060084135-A1 | Compositions for manipulating the lifespan and stress response of cells and organisms | BIOMOL INTERNATIONAL, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | BIOMOL INTERNATIONAL, INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005069998-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY TECHNOLOGY TRANSFER OFFICE (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813934-B2 | Sirtuin modulators as inhibitors of cytomegalovirus | SIRT1, SIRT2, SIRT7 | LMNA 3882/4885MAPT 2621/4885KDM4E 700/4885 |
| US-11014947-B2 | Lipophenol compounds and uses thereof | LPO, CBR1, LCLAT1 | LMNA 2273/4885MAPT 4789/4885KDM4E 1453/4885 |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | ATG7, SQSTM1, ATF4 | LMNA 2342/4885MAPT 3091/4885KDM4E 1284/4885 |
| US-20100185006-A1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND PROCESSES FOR MAKING THE SAME | SIRT1, SIRT2, SIRT3 | LMNA 1305/4885MAPT 4298/4885KDM4E 438/4885 |
| US-20200360334-A1 | New Uses of Lipophenolic Compounds | MALT1, CCR1, LIPG | LMNA 3701/4885MAPT 4670/4885KDM4E 4041/4885 |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | SIRT1, SIRT7, SIRT5 | LMNA 1010/4885MAPT 3039/4885KDM4E 640/4885 |
| US-11419841-B2 | Uses of lipophenolic compounds | MALT1, LIPG, CCR1 | LMNA 3017/4885MAPT 4652/4885KDM4E 3919/4885 |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | RB1, SBK1, NADK | LMNA 1421/4885MAPT 4496/4885KDM4E 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.